Patents Assigned to Biomed
  • Patent number: 9321798
    Abstract: Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR?R? where R? is H and R? is CR5R6CO2R7, where R6 is H, R5 is the side chain, including H and C1, of a naturally occurring alpha amino acid, and R7 is branched or unbranched, substituted or unsubstituted, acyclic or cyclic alkyl, including t-butyl-CH2-, benzyl and C3 to C6 cycloalkyl. Formula (I).
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: April 26, 2016
    Assignee: NuCana BioMed Limited
    Inventor: Christopher McGuigan
  • Patent number: 9283187
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 15, 2016
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Publication number: 20160008509
    Abstract: The invention relates to novel collagen materials and, specifically, collagen membranes, tubes and threads. Said materials combine enhanced properties of resilience and strength. The invention also relates to a method for preparing collagen materials using acid fibrous collagen comprising coagulation and, optionally, cross-linking of the collagen in the presence of ammonia gas.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 14, 2016
    Applicant: BIOM'UP
    Inventors: Christian GAGNIEU, Patricia FOREST, Sylvain PICOT
  • Patent number: 9228011
    Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: January 5, 2016
    Assignee: Lykera Biomed SA
    Inventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
  • Patent number: 9221866
    Abstract: Phosphoramidate derivatives of 5-fluoro-2?-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: December 29, 2015
    Assignee: NuCana Biomed Limited
    Inventors: Christopher McGuigan, Jan Balzarini, Magdalena Slusarczyk, Blanka Gonczy, Paola Murziani
  • Patent number: 9205963
    Abstract: A thermoplastic, biodegradable polymer blend having a high surface energy and good adhesion without the need for pretreatment, is made up of starch in the range 10% to 60% by weight of the polymer blend, at least one further carrier polymers in the range 40% to 90% by weight of the polymer blend and one or more process aids in the range 0% to 0.5% by weight of the polymer blend. The polymer blends typically have a surface energy after processing of at least 40 mN/m.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: December 8, 2015
    Assignee: Biome Bioplastics Limited
    Inventors: Paul William Law, Tony Longdon, Daniel Arnillas Perez, Maria Begona Gomis Gomis
  • Patent number: 9168326
    Abstract: The invention relates to novel collagen materials and, specifically, collagen membranes, tubes and threads. Said materials combine enhanced properties of resilience and strength. The invention also relates to a method for preparing collagen materials using acid fibrous collagen comprising coagulation and, optionally, cross-linking of the collagen in the presence of ammonia gas.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: October 27, 2015
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Patent number: 9131972
    Abstract: A screw for fixing vertebra for letting a patient perform spinal motion more smoothly after a pedicle screw insertion surgery is disclosed. A head portion of the screw body is pivotally joined in sliding contact on the head seat portion of a movable washer, which is also pivotally joined in sliding contact on the washer seat portion of a fastening nut. A first aperture and a second aperture are formed in the fastening nut and movable washer respectively, and an elongating portion without a thread is formed between a screw portion and the head portion of the screw body.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 15, 2015
    Assignee: L&K Biomed Co., Ltd.
    Inventors: Gook-Jin Kang, Choon-Sung Lee
  • Patent number: 9097731
    Abstract: A method for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by a heparin substance, such as thrombocytopenia induced by heparin (HIT type II) as inducer drug. The method includes the steps of reacting at least one substance with high affinity for a heparin substance (SFA), with at least one heparin substance (SH) so as to form a substance with high affinity for heparin-heparin substance (SFA-SH) complex. The heparin substance is adapted to bind other substances with affinity for heparin and with at least one potential antigenic substance capable of reacting with the heparin substance, forming a (Ag-SH) complex. The method further includes the steps of testing a patient's plasma or serum potentially containing an anti(Ag-SH) antibody after administration of the heparin substance and revealing the resulting (Ag-SH)-anti(Ag-SH) complex produced.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: August 4, 2015
    Assignee: Hypen Biomed
    Inventors: Jean Amiral, Anne-Marie Vissac
  • Patent number: 9072802
    Abstract: Systems and methods for disinfecting medical instruments are provided. In one embodiment, a system can include a hood to provide a clean zone, a chamber to dispose within the clean zone, and an ultrasonicator. More specifically, the chamber can include a volume and can be configured to retain a fluid and receive medical instruments. The chamber can also include a portal through which fluids enter or leave the chamber. The ultrasonicator can be used to sonicate the volume when the fluid is present. A related method of disinfecting medical instruments can be accomplished using the systems of the present disclosure.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 7, 2015
    Assignee: Solutions BioMed, LLC
    Inventors: Brian G. Larson, Daryl J. Tichy
  • Patent number: 9062186
    Abstract: A bio-resin composition contains cellulose acetate and a biodegradable secondary polymer in a ratio of at least 10:1 by weight of the total weight of the composition wherein the secondary polymer is an aliphatic polyester such as polybutylene succinate or an aliphatic co-polyester such as polybutylene succinate adipate or an aliphatic/aromatic polyester such as polybutylene adipate terephthalate. The secondary polymer may be present in an amount up to 10% by weight, more preferably up to 6% by weight and more preferably still in the range 2% to 3% by weight of the total weight of the composition where the combined amount of secondary polymer and cellulose acetate may be up to 85% of the total weight of the composition.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 23, 2015
    Assignee: Biome Bioplastics Limited
    Inventors: Tony Longdon, Paul William Law, Kevin Sillence, David John Wetters, Daniel Arnillas Perez
  • Patent number: 9017695
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule. Also disclosed are particles and compositions that include the disclosed chimeric therapeutics.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Biomed Realty, L.P.
    Inventors: Miguel de los Rios, Stephanie de los Rios
  • Patent number: 9012238
    Abstract: Implantable devices comprise at least one or more targeting molecules that form a primary coating layer for selectively recruiting, isolating, activating, and/or eliminating any cells of interest, such as T cells, monocytes, and stem cells. The implantable devices can be utilized for selectively removing a particular subset of cells from bodily fluids of a patient. Various non-selective pharmaceutical agents and biological agents can be incorporated into the implantable devices so that cells of interest can be isolated for elimination or for activation/differentiation. Cell-type selectivity is conferred by the presence of cell-type-specific targeting molecules incorporated into the implantable device, preferably at the surface level to permit direct or indirect interaction between the cells of interest and targeting molecules of the implantable device. Related therapeutic methods for utilizing the implantable devices are also provided.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: April 21, 2015
    Assignee: Biomed Solutions, LLC
    Inventors: Kendrick Goss, Carol Gebert
  • Patent number: 9011923
    Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: April 21, 2015
    Assignees: Innovata Biomed Limited, Vectura Limited
    Inventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
  • Patent number: 8991213
    Abstract: A method by which recovered glass from waste steams can be used to create a closed cell foam glass in the 9 to 13 lbs/ft3 density range using a single-step foaming process. The waste glass is mixed with foaming agents and the boron content is adjusted and maintained between 7 to 14% of the mixture. The mixture is formed into a charge and fired at a temperatures ranging from 100° C. to 250° C. above the softening point of the waste glass for a controlled period of time. The waste glass can be obtained from commercial waste streams of high borosilicate glass to common container glass from recycling sources. The glass is ground to an appropriate size and mixed with fluxes, enhancers, and foaming agents which are then properly dispersed within the mixture.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: March 31, 2015
    Assignee: Biome International, Inc.
    Inventors: Victor Flack, Andrew Bernard, Steven Blome
  • Patent number: 8987331
    Abstract: The present disclosure is drawn to a disinfectant system which can be used to disinfect surfaces. The system includes a first chamber containing a first solution and a second chamber containing a second solution. The first solution can include an alcohol, an organic carboxylic acid, and from 0.01 ppm, to 1,000 ppm by weight of a transition metal or alloy thereof based on the first solution weight content. The second solution can include hydrogen peroxide. The system further includes a dispenser through which the system is configured to mix and dispense the first solution and the second solution immediately before being dispensed. A peracid composition is formed upon mixing of the first and second solutions.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: March 24, 2015
    Assignee: Solutions BioMed, LLC
    Inventors: Brian G. Larson, Daryl J. Tichy
  • Patent number: 8975241
    Abstract: There is provided a composition for preventing and treating obesity including high water-soluble ?-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble ?-cyclodextrin derivatives, especially, 2-hydroxypropyl-?-cyclodextrin (HP-?-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: March 10, 2015
    Assignee: Song Ho Biomed Co., Ltd.
    Inventors: Gyoon-Hee Han, Yong Seok Choi, Sang-Bae Han, Jong-Ho Lee, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Jong-Soon Kang, Ki-Hoon Lee, Chang-Woo Lee
  • Publication number: 20150056254
    Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.
    Type: Application
    Filed: February 7, 2013
    Publication date: February 26, 2015
    Applicant: PHI BioMed Co., Ltd.
    Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
  • Publication number: 20150045395
    Abstract: This invention relates to methods of reversing and inhibiting liver fibrosis and hepatitis using a small indolinone molecule Hesperadin and related compounds. Methods of identifying such agents and using them to inhibit the expression of collagens and ECM proteins including MMPs and TIMPs in purified hepatic stellate cells are provided. In vivo data of Hesperadin in inhibiting induced collagen production are presented. This method of specifically targeting drugs to hepatic stellate cells in vivo, provides a novel therapy for liver diseases.
    Type: Application
    Filed: August 9, 2013
    Publication date: February 12, 2015
    Applicant: Acclaim BioMed USA LLC
    Inventors: Kenneth Ka-Ho Lee, Stanton Hon-Lung Kok, Tsz-Wai Kok, Sing-Wan Wong, John Yeuk-Hon Chan
  • Patent number: 8948474
    Abstract: A quantification method and an imaging method are disclosed, capable of quantifying the margin feature, the cysts feature, the calcifications feature, the echoic feature and the heterogenesis feature of a tumor, and capable of imaging the margin feature, the cysts feature, the calcifications feature and the heterogenesis feature of a tumor. The quantification method and the imaging method calculate the moving variance of the gray scale of each of the pixel points based on the gradient value of the gray scale of these pixel points. Then, depending on the purpose of the quantification method or the imaging method, the maximum value, the minimum value, the mean value, and the standard deviation of the moving variance of the gray scale of these pixel points are calculated, respectively. At final, with the definition of the threshold value and the imaging rule, the above features of the tumor are quantified or imaged.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: February 3, 2015
    Assignee: Amcad BioMed Corporation
    Inventors: King Jen Chang, Wen Hwa Chen, Argon Chen, Chiung Nein Chen, Ming Chih Ho, Hao Chih Tai, Ming Hsun Wu, Po Wei Tsai, Chung Wei Liu, Hsin-Jung Wu